The distribution of gamma-aminobutyric acid (GABA)-ergic neurons in the postmortem human cerebellar cortex and dentate nucleus was studied using antibodies against glutamate decarboxylase (GAD) and two different cytoplasmic calcium-binding proteins, parvalbumin and calbindin D-28k (CaBP), and the alpha-subunit of the GABAA/benzodiazepine receptor protein. The cerebellum of normal controls was compared to those of patients with senile dementia of the Alzheimer type (SDAT) in order to determine the involvement of these neurons in the dementing disorder. In the normal human cerebellar cortex all neuronal types except granule cells were GAD-labeled. Immunoreactivity was found predominantly in axonal structures, particularly in basket plexus around Purkinje cell somata. Antibodies against CaBP specifically stained all Purkinje cells in their entirety including axons and dendritic spines. Parvalbumin immunoreactivity was found in a subpopulation of Purkinje cells, basket and stellate cells but not in Golgi and granule cells. Parvalbumin-immunoreactive basket plexuses were found around Purkinje cell somata. The most intense labeling with the GABAA/benzodiazepine receptor antibody was found on the surface of granule cells. Purkinje, basket and stellate cells showed only a weak labeling of their surface. In the dentate nucleus only small neurons showed GAD immunoreactivity. Large neurons were densely covered with labeled axons and varicosities. No cell somata were stained with antibodies against CaBP and parvalbumin. All types of large and small dentate neurons showed immunoreactivity against GABAA/benzodiazepine receptor protein on the surface of their soma and dendrites. SDAT is accompanied by some changes in neurons belonging to the GABA subset. Fewer spines were found on the dendrites of Purkinje cells and on large dentate neurons. In the granular layer, more Purkinje axonal deformations ('torpedoes') and a hypertrophic network of Purkinje axon collaterals were found.

Keywords:
Alzheimer, Calcium-binding proteins, Cerebellum, GABA, Receptor
This content is only available via PDF.
© 1990 S. Karger AG, Basel
1990
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.